1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,170 | 1,190 | 07.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10. | As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides | 745 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 27, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, explained... ► Artikel lesen | |
| 06.10. | NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 | 1.203 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("the Company") is pleased to announce that it will be presenting tomorrow October 7, 2026 at NIBA's 153rd... ► Artikel lesen | |
| 29.09. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 29.09. | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials | 936 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 28.09. | NANOVIRICIDES, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 28.09. | Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week, Says NanoViricides | 611 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| 23.09. | Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox Has Begun in DRC, Announces NanoViricides | 947 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral... ► Artikel lesen | |
| 15.09. | NanoViricides, Inc.: Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides | 1.325 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| 08.09. | NanoViricides: Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo | 1.179 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces... ► Artikel lesen | |
| 31.08. | While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles | 865 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 18.08. | NanoViricides: The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon | 1.346 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 10.08. | NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak | 11.027 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 30.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 9 | SEC Filings | ||
| 28.07. | NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial | 9.294 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 24.07. | NanoViricides announces $3.8M registered direct offering; shares down | 5 | Seeking Alpha | ||
| 24.07. | NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering | 1.614 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 22.07. | As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola | 9.018 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 17.07. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.07. | As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo | 855 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that... ► Artikel lesen | |
| 08.07. | Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily | 963 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a... ► Artikel lesen |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 13,920 | -1,14 % | Formycon Aktie: Keytruda-Nachahmer könnte zum Milliarden-Türöffner werden | Für Formycon rückt mit dem Biosimilar-Kandidaten FYB206 der wichtigste Werttreiber des Unternehmens näher an eine mögliche Markteinführung. Die US-Arzneimittelbehörde FDA hat den Zulassungsantrag für... ► Artikel lesen | |
| VEECO INSTRUMENTS | 31,100 | 0,00 % | Axcelis Technologies and Veeco Instruments Provide Update on Expected Timing of Merger Closing | Merger now expected to close by the end of the first quarter of 2027 BEVERLY, Mass., and PLAINVIEW, N.Y., Nov. 2, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS) ("Axcelis") and Veeco... ► Artikel lesen | |
| ONTO INNOVATION | 156,00 | +0,35 % | Onto Innovation: Diese KI-Aktie ist ein Favorit für 2027 | Die Aktie von Onto Innovation ist im Zuge der jüngsten Gewinnmitnahmen bei Halbleiterwerten deutlich unter Druck geraten. Angesichts starker Geschäftszahlen und wachsender Nachfrage durch den KI-Boom... ► Artikel lesen | |
| RIBER | 5,740 | 0,00 % | Riber Reports Improved Results For The First Half Of 2026 | RIBER REPORTS IMPROVED RESULTS FOR THE FIRST HALF OF 2026 Revenues of €12.7m (+19%) and gross margin of €5.1m (+31%), representing 39.8% of revenuesPositive net income of €0.2m, compared with -€0.8m... ► Artikel lesen | |
| LAMPETIA | 0,124 | +6,90 % | EQS-Adhoc: Lampetia AG: Verkauf der Lampetia Investments Engineering Ltd geplant | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Mergers und Acquisitions / Verkauf von Unternehmensteilen
Lampetia AG: Verkauf der Lampetia Investments Engineering Ltd geplant
06.11.2026... ► Artikel lesen | |
| KOPIN | 2,607 | -4,30 % | Fabric.AI (Nasdaq: FABC) Stockholders Ratify Kopin Strategic Partnership to Develop Neural I/o MicroLED Optical Interconnect Technology for Next Generation AI Data Centers | NEW YORK, NY, June 24, 2026 (GLOBE NEWSWIRE) -- Fabric.AI, Inc. (Nasdaq: FABC) ("Fabric.AI" or the "Company"), a fabless semiconductor company developing MicroLED-based optical interconnects for AI... ► Artikel lesen | |
| GAUZY | 5,950 | -3,25 % | Research Frontiers expects material royalty recovery after Q4 2026 as Gauzy restarts SPD production | ||
| GOMSPACE | 1,055 | +1,05 % | GomSpace Group AB: GomSpace reports continued profitable growth in Q3 and narrows full year guidance | GomSpace reports continued profitable growth in Q3 and narrows full year guidance
GomSpace delivers revenue growth with a 14% EBITDA margin in Q3 and sets 2030 financial targets of SEK 1.6 billion... ► Artikel lesen | |
| OBDUCAT | 0,030 | 0,00 % | NGM MARKET NOTICE: #26-72 Decision by the Disciplinary Committee regarding Obducat AB (publ) | ||
| SOLESENCE | 0,850 | -0,83 % | Solésence, Inc.: Solésence Reports Second Quarter 2026 Financial Results | Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically... ► Artikel lesen | |
| ZENTEK | 0,330 | -1,20 % | Zentek Ltd.: Zentek Provides Corporate Update on Nasdaq Listing | Guelph, Ontario--(Newsfile Corp. - October 26, 2026) - Zentek Ltd. (TSXV: ZEN) (OTCQX: ZTEKF) ("Zentek" or the "Company") today provides an update on the Nasdaq appeal process it began after The Nasdaq... ► Artikel lesen | |
| ACACIA RESEARCH | 3,740 | +5,06 % | ACACIA RESEARCH CORP - 10-K/A, Annual Report | ||
| NVE | 62,00 | 0,00 % | Dividendenbekanntmachungen (02.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABM INDUSTRIES INC US0009571003 0,29 USD EUR ACUITY INC US00508Y1029 0,2 USD EUR AMERISERV FINANCIAL INC US03074A1025 0,03... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,302 | -0,66 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| DOTZ NANO | 0,007 | +121,21 % | DOTZ Nano signs five-year ChillerAI agreement in Israel |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell +2,65 % bei einem Aktienkurs von 1,160 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.